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Introduction: Giant cell arteritis (GCA) is characterized by intimal hyperplasia leading to ischaemic manifestations
that involve large vessels. Neurotrophins (NTs) and their receptors (NTRs) are protein factors for growth,
differentiation and survival of neurons. They are also involved in the migration of vascular smooth muscle cells
(VSMCs). Our aim was to investigate whether NTs and NTRs are involved in vascular remodelling of GCA.
Methods: We included consecutive patients who underwent a temporal artery biopsy for suspected GCA. We
developed an enzymatic digestion method to obtain VSMCs from smooth muscle cells in GCA patients and
controls. Neurotrophin protein and gene expression and functional assays were studied from these VSMCs.
Neurotrophin expression was also analysed by immunohistochemistry in GCA patients and controls.
Results: Whereas temporal arteries of both GCA patients (n = 22) and controls (n = 21) expressed nerve growth
factor (NGF), brain-derived neurotrophic factor (BDNF), tropomyosin receptor kinase B (TrkB) and sortilin, immunostaining
was more intense in GCA patients, especially in the media and intima, while neurotrophin-3 (NT-3) and P75 receptor
(P75NTR) were only detected in TA from GCA patients. Expression of TrkB, a BDNF receptor, was higher in GCA patients
with ischaemic complications. Serum NGF was significantly higher in GCA patients (n = 28) vs. controls (n = 48), whereas
no significant difference was found for BDNF and NT-3. NGF and BDNF enhanced GCA-derived temporal artery VSMC
proliferation and BDNF facilitated migration of temporal artery VSMCs in patients with GCA compared to controls.
Conclusions: Our results suggest that NTs and NTRs are involved in vascular remodelling of GCA. In GCA-derived
temporal artery VSMC, NGF promoted proliferation and BDNF enhanced migration by binding to TrkB and p75NTR
receptors. Further experiments are needed on a larger number of VSMC samples to confirm these results.Introduction
Giant cell arteritis (GCA) is a primary vasculitis involv-
ing aorta and its extra- and intracranial branches. Histo-
pathological findings show cellular infiltrates, internal
elastic lamina disruption and intimal hyperplasia, leading
to luminal stenosis. Macrophages and giant cells produce
platelet-derived growth factor (PDGF), which stimulates
migration of vascular smooth muscle cells (VSMCs) from
the media to the intima to initiate intimal hyperplasia.* Correspondence: kim.ly@chu-limoges.fr
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stated.However, several mechanisms involved in vascular remod-
elling of GCA still remain unclear [1].
Neurotrophins (NTs) are growth factors initially de-
scribed in the nervous system and now include vascular
cells [2]. Three NTs and their receptors (NTRs) are
well investigated. They include the nerve growth factor
(NGF), brain-derived neurotrophic factor (BDNF) and
neurotrophin-3 (NT-3), the selective tropomyosin recep-
tor kinase (Trk), TrkA for NGF, TrkB for BDNF and
TrkC for NT-3, a non-selective receptor p75NTR and a
co-receptor, which is usually associated with p75NTR,
called sortilin. In the cardiovascular system, NTs and
NTRs are involved in cardiovascular development, blood
vessel growth, VSMCs and cardiomyocyte functions [2].
NTs and NTRs are detected in vivo and in vitro in endo-
thelial cells and human aortic VSMC donors and in ratsThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
Table 1 Clinical and biological findings in the study
cohort patients with GCA









Number of patients 30 22 42
General characteristics
Age in years, median
(range)
77 (60-92) 80.7 (73-89) 76.3 (60-92)
Sex, women/men 23/7 14/8 30/12
Systemic manifestations 15 (50) 17 (77) 33 (78.5)
Fever 9 (30) 4 (18) 13 (31)
Weight loss 15 (50) 12 (54.5) 20 (47.6)
Cranial symptoms 21 (70) 14 (63.6) 31 (73.8)
Headache 21 (70) 14 (63.6) 31 (73.8)
Jaw claudication 15 (50) 11 (50) 19 (45.2)
Scalp tenderness 14 (46.6) 12 (54.5) 21 (50)
Abnormal temporal
arteries*
13 (43) 7 (32) 7 (16.6)
Cranial ischaemic events 9 (30) 8 (36) 11(26)
Permanent visual loss 1 (3) 3 (13.6) 2 (4.7)
Amaurosis fugax 6 (20) 8 (36) 11 (26)
Stroke 2 (6.6) 1 (4.5) 3 (7)
Polymyalgia rheumatica 7 (23) 7 (32) 10 (24)




C-reactive protein (mg/L) 102.2+/-70.3 92.6+/-66 86.2+/-78
Platelet count (x 109/L) 476+/-157 484+/-162 448+/-150
Haemoglobin (g/L) 11.5+/-1.6 12.2+/-1.4 11.8+/-1.7
*Abnormal temporal arteries at physical examination (painful, swollen,
indurated and/or with decreased or absent pulsation). GCA, giant cell arteritis;
IHC, immunohistochemistry; SD, standard deviation.
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as PDGFs, but not their proliferation [3,4]. Moreover,
NGF and BDNF and their two specific Trk receptors are
involved in aortic intimal hyperplasia induced by balloon
angioplasty in rats [3], while activation of p75NTR by
NGF, NT-3 and, to a lesser extent, BDNF, induce VSMC
apoptosis [5].
Using temporal artery VSMCs (TASMCs) obtained
prospectively from suspected GCA patients, we hypoth-
esized that NTs and NTRs are involved in the patho-




We prospectively enrolled patients who had undergone
a temporal artery biopsy (TAB) for suspected GCA at
Limoges and Paris (Cochin and Hotel-Dieu) university
hospitals, since January 2010. GCA diagnosis was estab-
lished according to American College of Rheumatology
(ACR) criteria and biopsy-proven GCA lesions [6]. Pa-
tients with a negative TAB without clinical diagnosis of
arteritis were defined as controls. All subjects gave their
informed consent prior to participation and the study
was approved by the Ethics Committee of the Cochin
University of Paris (collection dc-2010-1079). Clinical
and biological data are shown in Table 1.
Cell culture
TASMCs were isolated from segments of 5 to 10 mm of
temporal artery (TA) after removal of adventitia and
enzymatic digestion of media with 500 U/mL of type I
collagenase in 5 mL of Dulbecco’s modified Eagle’s
medium (DMEM) Glutamax II (Gibco, Grand Island, NY,
USA). Cultures were performed, as previously described
[7], in Smooth Muscle Cell Basal Medium (PromoCell,
Heidelberg, Germany) supplemented with foetal calf
serum (FCS) (5%), insulin (5 μg/mL), fibroblast growth
factor (FGF-2) (2 ng/mL), epidermal growth factor
(0.5 ng/ml) and streptomycin/penicillin (1%) at 37°C
in 5% CO2. Functional assay cells were growth factor-
starved and maintained in DMEM-free medium for
24 h before stimulation.
Cultures contained 90% VSMC cells expressing α-
smooth-muscle actin (Sigma-Aldrich, St Louis, MO,
USA), without CD-90 fibroblastic staining (Dianova,
Hamburg, Germany) (Additional file 1). TASMCs were
used for the experiments between passages 3 and 8. The
cells were studied for NTs and NTRs expression at protein
and transcriptional levels and in proliferation and migra-
tion assays. GCA-derived TASMCs used for western blot-
ting, real-time polymerase chain reaction (PCR) analysis
and functional assays were obtained from patients with
positive TAB for GCA.Immunohistochemistry
Immunohistochemistry was performed on paraffin-
embedded sections of TA deparaffinised in 22 biopsy-
proven GCA patients according to previous described
criteria [8] and 21 controls with rabbit anti-NGF,
-BDNF, -NT-3, -TrkA, -TrkB, -TrkC, -p75NTR and goat
anti-sortilin antibodies (Ab) (Santa Cruz, Heidelberg,
Germany) at 1:100 and anti-CD3 Ab for T lymphocytes
(1/400; Dako Glostrup, Denmark). Sections of TA were
rehydrated and subjected to steam-heat antigen re-
trieval in citrate buffer in a microwave oven (750 W).
Endogenous peroxidases were inhibited with 5% H2O2
in methanol and non-specific sites were blocked with
phosphate-buffered saline (PBS)-3% bovine serum albumin.
The primary Ab as above were incubated at a 1/100 dilu-
tion overnight at 4°C and revealed with the anti-rabbit
HRP Envision™ (Dako). After counterstaining, the slides
were studied with a Leica microscope (×200 magnification)
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using a staining index based on the percentage of positive
cells. Positive controls were obtained from neuroblastoma
and breast cancer tissues. Negative controls were done
with isotypic immunoglobulin controls (data not shown).
To perform semi-quantitative measurement of immuno-
staining, we chose three representative area of temporal
artery (×200 magnification) to count staining cells that
expressed myofibroblast or VSMC phenotype (that is,
elongated cells). The mean of positive cell percentage of
these three measurements for each patient or control was
used to determine immunostaining intensity. The results
were expressed as the mean of three independent quantifi-
cations made by two different observers.
Western blotting
Western blotting was performed as previously described
[9] with rabbit anti-NGF, -BDNF, -NT-3, -TrkA, -TrkB,
-p75NTR and goat anti-sortilin Ab (Santa Cruz) or anti-
TrkC (R&D Systems, Minneapolis, MN, USA) at 1/200
dilution. Signalling activation was studied by using
rabbit anti-protein kinase B (Akt) and -phospho-Akt Ab
and -phospho-extracellular signal-regulated kinase (Erk)
1/2 and mouse anti-Erk1/2 Ab (at 1/1000 dilution; R&D
Systems). Proteins (50 μg/lane) obtained from whole-cell
lysates of TASMCs using lysis buffer [9] were sepa-
rated on 10 to 12% SDS-polyacrylamide gels (Invitrogen,
Carlsbad, CA, USA) and transferred onto PVDF mem-
branes (Merck Millipore, Billerica, MA, USA). After sat-
uration (5% nonfat dry milk, 0.1% Tween in PBS), Ab
were incubated overnight at 4°C, and revealed after 1 h
incubation at room temperature (RT) with anti-rabbit
or -goat Ig-HRP-conjugated Ab (Santa Cruz, dilution
1/1000) by chemiluminescence (ECL reagent; Amersham,
Little Chalfont, UK). Protein-loading control was per-
formed with anti-actin Ab (Santa Cruz, 1/10,000). Western
blots were scanned using a bioimaging system (Genesnap;
Syngene, Cambridge, UK).
RNA extraction, reverse transcription and real-time
PCR assays
Total RNAs were extracted with Qiagen RNeasy Isolation
Kit (Qiagen, Venlo, Netherlands), treated with RNase-free
DNase I (Qiagen), and quantified by NanoDrop (ND-1000)
spectrophotometer (NanoDrop, Wilmington, DE, USA).
The RNA quality was evaluated on an Agilent 2100
bioanalyzer using the RNA 6000 Labchip kit (Agilent
Technologies, Palo Alto, CA, USA). cDNA synthesis was
performed with a High-Capacity cDNA Reverse Transcrip-
tion Kit (Applied Biosystems, Carlsbad, CA, USA), as rec-
ommended by the manufacturer. Real-time PCR was
performed by predesigned primer/probe TaqMan gene ex-
pression assays (Applied Biosystems) and normalized to
HPRT housekeeping gene (Additional file 2). Experimentswere assessed in triplicate at least using TaqMan Fast-
Univ Master Mix (Applied Biosystems) using an Applied
Biosystems StepOnePlus Real-Time PCR System and ana-
lysed by StepOne Software v2.2.2 with a two-step PCR
protocol as previously described [9]. The comparative ΔCt
method was used for relative quantification of gene expres-
sion on duplicate of each reaction.
Cell viability, proliferation and chemoinvasion assays
Cell viability, proliferation and migration assays were
studied using exogenous NGF (Alomone Labs, Jerusalem,
Israel), recombinant human BDNF (Promega, Madison,
WI, USA), or PDGF-AB (R&D Systems, Minneapolis,
Minnesota, USA), alone or both with K252a, a pharmaco-
logical Trk inhibitor (Alomone), ANA-12 (100 μM), a spe-
cific TrkB inhibitor, acting without altering TrkA and TrkC
functions (Tocris, Bristol, UK) [10] or an anti-p75NTR an-
tagonist Ab (Alomone).
Cell viability of TASMCs was assessed using the col-
orimetric XTT assay (Cell Proliferation Kit II, XTT,
Roche, Basel, Switzerland) according to the manufac-
turer’s instructions. A range of concentrations was evalu-
ated for each of the conditions studied (Additional file 3).
Efficient concentrations were defined as follows: NGF
(10 ng/mL), BDNF (200 ng/mL), K252a Trk inhibitor
(100 ng/mL), ANA-12 (100 μM), anti-p75NTR antagonist
Ab (10 mg/mL) and PDGF (40 ng/mL), which was used as
a positive control [11].
Cell proliferation was determined by incorporation of
BrdU (Cell Signaling, Danvers, MA, USA) according to
the manufacturer’s instructions. Assays were studied
using recombinant human NGF (10 ng/mL), recombin-
ant human BDNF (200 ng/mL), or recombinant human
PDGF-AB (40 ng/mL), alone or both with K252a Trk in-
hibitor (100 ng/mL), or ANA-12 specific TrkB inhibitor
(100 μM) or an anti-p75NTR antagonist Ab (10 mg/mL).
Efficient concentrations of exogenous NTs, PDGF and NT
receptor inhibitors were previously determined with XTT
assay. Cells were seeded in 96-well plates (5,000 cells/well)
and maintained in DMEM-free serum medium during
48 h before stimulation. Proliferation assays were per-
formed after one, three and four days of TASMC incuba-
tion with NT or NTR inhibitors, or both.
Chemoinvasion assay
The Boyden chamber method was performed in a BD
Biocoat Matrigel Invasion Chambers (BD Biosciences,
Franklin Lakes, NJ, USA) with an 8-μm pore-size
membrane for the chemoinvasion assay. Experiments
were performed in duplicate in at least two independ-
ent experiments. Serum-starved TASMCs were seeded
(1 × 105 cells/well) in 500 μL of serum-free DMEM into
the upper chamber of the membrane-embedded insert
during 48 h before stimulation. DMEM containing either
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trations defined above were placed in the lower cham-
ber and the cells were incubated for 24 or 48 h at 37°C/
5% CO2. After incubation, the lower chamber was
treated with 50 μM Calcein AM fluorescent dye for
30 min at 37°C/5% CO2. Non-invading cells in the
upper part of the insert were carefully removed. Then,
8 μl of Calcein AM fluorescent dye (BD Biosciences)
was added for 15 min to the lower chamber. Non-
invading cells in the upper part of the insert were care-
fully removed. The migration of TASMCs to the lower
part was quantified by fluorescent counting spectropho-
tometry at 488 nm (Berthold, Bad Wildbad, Germany)
and images were obtained using a fluorescence micro-
scope M2FLIII (Leica).
Measurement of sera and supernatant neurotrophin
secretion
Cell-culture medium was collected and centrifuged for
30 min at 3,000 g in Vivaspin columns (Merck Millipore).
Concentrations of NGF, BDNF and NT-3 in TASMC
supernatant and 1:100 diluted sera from GCA patients and
controls were measured using enzyme-linked immuno-
sorbent assay (ELISA) kits according to the manufacturer’s
instructions (NGF or BDNF or NT-3 EmaxH ELISA,
Promega).
Statistical analysis
Results were expressed as their means ± standard errors of
the mean (SEM) of at least three independent experi-
ments. Statistical analyses were performed using Student’s
t test; a P value <0.05 was considered statistically signifi-
cant. Asterisks in figures indicate statistically significant
differences: *P <0.05, **P < 0.01, ***P <0.001.
Results
Neurotrophins are overexpressed in temporal arteries
from patients with GCA compared to controls
TAs from 22 GCA patients and 21 controls expressed
NGF, BDNF, TrkB and sortilin, whereas TrkA and TrkC
were not detected in any studied TAs (Figure 1A). How-
ever, significant differences in the intensity and location
of staining were observed between GCA patients and
controls. Indeed, NGF expression was more intense in
the adventitia (76.2 +/- 19 vs. 35.4 +/- 22%, P = 0.002)
and the media (59.6 +/- 25% vs. 26 +/- 22%, P = 0.004),
respectively. BDNF was markedly expressed in the media
(82 +/- 21 vs. 26.5 +/- 27%, P <0.0001) and the intima
(78 +/- 20 vs. 36 ± 27%, P = 0.0007), respectively. Con-
cerning sortilin, expression was prominent in the adventitia
(31 ± 28 vs. 2 ± 4%, P = 0.003) and the intima (41 ± 14 vs.
27 ± 14%, P = 0.02), respectively (Figure 1B). Interestingly,
only GCA arteries strongly expressed NT-3 and P75NTR in
all artery layers (Figure 1A).By contrast, T lymphocytes (anti-CD3+) staining was
localized in the media intima junction.
To search for a relationship between these expressions
and the course of the disease, we evaluated the staining
of NTs and NTRs in association with the clinical param-
eters of the 22 GCA patients (Table 1).
TrkB is overexpressed in temporal arteries of GCA
patients with ischaemic complications
Strikingly, only GCA patients with ischaemic events
(stroke, amaurosis or permanent visual loss) (n = 9)
had significant overexpression of TrkB in the media
(P = 0.04) and intima (P = 0.015), compared to GCA
patients without ischaemia (n = 13) (Figure 1C). No
difference in expression of NTs and NTRs was found
in the TAs of GCA patients regarding other clinical
characteristics or inflammatory biomarkers. Moreover,
we did not find any difference in immunostaining of
NTs and NTRs between GCA patients who received
corticosteroids before a TAB (n = 14) and untreated
patients (n = 8).
Considering these differences in the expression of NTs
and NTRs on ex vivo TAs in GCA patients, we achieved
primary cultures for six TAs from biopsy-proven GCA
patients and from 10 suspected GCA patients who had
normal histological TAs as controls.
Expression of neurotrophins and receptors in TASMCs
from the temporal arteries of GCA patients and controls
Protein expression was assessed by western blotting in
proteins extracted from the TASMCs of GCA patients
and controls (Figure 2A). Whereas NGF, BDNF, TrkB,
TrkC, p75NTR and sortilin were detected in TASMCs
from patients and controls, proteins for TrkA receptor
were not detected in cells from either of these groups. In
contrast, NT-3 protein was only detected in GCA and
not in control cells. Exploration of signalling pathways at
baseline showed that phospho-Akt is predominantly de-
tected in GCA-derived TASMCs than control. The ratio
of phospho-Akt/ Akt/actin is significantly higher in
GCA cells patients in comparison to patients controls
(P = 0.033) (Figure 2B) whereas no difference was found
for ERK 1/2 and phospho-ERK 1/2. In parallel, we have
confirmed by RT-PCR that the corresponding mRNAs
for NGF, BDNF, TrkB (truncated 95 length) and p75NTR
were present but not those for TrkA, as expected
(Figure 2B). However, some discrepancies were noted
between protein and mRNA expressions. This was evi-
denced for NT-3 mRNA, which was detected in all
sampled cells from patients and controls, and feebly for
the TrkC transcript. Therefore, a quantitative RT-PCR
was performed to determine the differences between
transcript expression of NT and NTR genes in cells
from patients and controls.
Figure 1 Immunostaining of NTs and their receptors and T lymphocytes (CD3+) in temporal arteries of patients and controls. (A) Panels
are representative examples of immunohistological images (x50 and x200) of temporal arteries from GCA patients (n = 22) compared to controls
(n = 21). (B). Panels are measurements of significant NT immunostaining intensities. Results are shown as mean values and standard errors of the
mean (SEM). (C) TrkB immunostaining in GCA patients with or without ischaemic complications. Immunoreactivity to TrkB in the media and
intima of TAs in GCA patients with (n = 9) or without (n = 13) ischaemic complications. GCA, giant cell arteritis; NT, neurotrophin; TA, temporal
artery; Trk, tropomyosin receptor kinase.
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Figure 2 Western blot (WB) analysis of GCA patients’ and controls’ TASMC lysates. WB analysis of GCA patients’ (n = 6) and controls’ (n = 4)
TASMC lysates for NTs and NT receptors (A) and for Akt, phospho-Akt, ERK 1/2 and phospho-ERK 1/2 and histograms for phospho-Akt /Akt/ actin
ratio (B). Panels are representative examples of WB analysis. (C) Transcription of NTs and NT receptors by TASMCs from GCA patients (n = 6) and
controls (n = 6) cultured with 10% FCS. The neuroblastoma cell line SH-SY-5Y (S) was used as a positive control. Constitutively expressed GAPDH
is a control of PCR efficiency. Panels are representative examples of the transcription assay. NC: negative control. (D) qRT-PCR analysis of NT and
NT receptor expression in TASMC cultures from GCA patients (n = 6) and controls (n = 6), normalized to HPRT gene expression. Akt, protein kinase B;
ERK, extracellular signal-regulated kinase FCS, foetal calf serum; GCA, giant-cell arteritis; NGF, nerve growth factor; NT, neurotrophin; PCR, polymerase
chain reaction; TASMC, temporal artery VSMC; VSMC, vascular smooth muscle cell.
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those of NT-3, TrkB, TrkC and sortilin were overex-
pressed (increase by fivefold) in TASMCs from GCA pa-
tients compared to controls, but the difference was not
significant (Figure 2C). Thus, because NGF and BDNF
and their receptors were detected in TASMCs from
GCA and control patients, the functional effects of these
two NTs were evaluated in cultured cells from TAs from
the two groups and compared with PDGF as a positive
control.Proliferation effects of NT and NT receptor blockers in
GCA patients
NGF promoted proliferation of TASMCs from GCA pa-
tients compared to controls (P = 0.025) similarly to FCS
(P = 0.012) and PGDF (P = 0.023) by day 1. BDNF tended
to enhance cell proliferation by day 1 especially in
TASMCs from GCA patients (P = 0.052) (Figure 3A).
Proliferation effects with NTs, FCS 10% and PDGF tended
to disappear by day 3 and day 4 with no difference be-
tween the two groups (Additional file 4). Addition of
Figure 3 Effects of NTs and the inhibitors of Trk (K252a), TrkB (ANA-12) and p75NTR (anti-p75) on TASMC proliferation in GCA patients
and controls. Proliferation assay performed with a BrdU assay on day 1 (A) in serum-starved TASMC incubated with NT or NT receptor inhibitors,
or a combination of NT and NT receptor inhibitors, in GCA patients (n = 6) and controls (n = 10). In all figures, bars represent the mean of three
experiments with their SEMs. K252a: specific Trk receptor inhibitor; ANA-12: a specific TrkB receptor inhibitor; anti-p75: p75NTR Ab inhibitor; N (NGF)
or B (BDNF) + K (K252a) or anti-p75NTR: NGF or BDNF are added at the same time with the specific inhibitor. (B) Effect of ANA-12 on GCA-derived
TASMCs proliferation. Three independent assays were performed and cells were seeded in triplicate for each cell line. BDNF, brain-derived
neurotrophic factor; GCA, giant-cell arteritis; NGF, nerve growth factor; NT, neurotrophin; SEM, standard errors of the mean; TASMC, temporal
artery VSMC; Trk, tropomyosin receptor kinase; VSMC, vascular smooth muscle cell.
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duce a significant difference between the two groups.
However, ANA-12 significantly decreased proliferation of
TASMCs from GCA in the presence of BDNF (P = 0.010),
demonstrating that BDNF-induced proliferation was de-
pending on TrkB activation (Figure 3B).
Given that NGF and, to a lesser extent, BDNF induced
proliferation in TASMCs from GCA patients compared
to controls, we searched for the potential effect of NTs
in TASMC invasion properties in Matrigel chambers to
determine whether NTs are involved in intimal hyper-
plasia as shown by immunohistochemistry.
BDNF activates TASMC migration in GCA patients but not
in controls
Comparison of TASMC invasion in GCA and control
patients demonstrated that TASMCs from GCA patientswere significantly able to migrate in the presence of
exogenous BDNF compared to those from controls
(P = 0.012) after a 24-h exposure (Figure 4). In contrast,
no effect was shown for exogenous NGF whatever the
status of TASMCs in patients or controls. Of note, only
cells from GCA patients were able to significantly in-
vade Matrigel chambers in the presence of 10% FCS
(P = 0.0175, compared to cells from controls) as was
also observed for exogenous PDGF (P <0.0001 vs. cell
migration in controls). Strikingly, neither BDNF nor
PDGF induced migration of TASMCs in controls. Migra-
tion of TASMCs in GCA patients was only detected after
a 24-h exposure and disappeared after 48 h of incubation
(data not shown).
Because NTs are expressed in TAs and in VSMCs of
GCA patients, we looked for secretions by TASMC cells
in cultures and the sera.
Figure 4 Migration assay of TASMC with NGF and BDNF. Migration
assays were performed with TASMCs from GCA patients (n= 6) and
controls (n= 6) incubated in the upper chamber with serum-free DMEM
during 48 h whereas NGF (10 ng/mL), BDNF (200 ng/mL), PDGF
(40 ng/mL) or 10% FCS were added in the lower chamber during
24 h. Top: representative images of the lower chamber after migration
and fluorescent staining. Bottom: data analysis obtained from two
independent assays performed with cells seeded in duplicate for each
cell line. BDNF, brain-derived neurotrophic factor; DMEM, Dulbecco’s
modified Eagle’s medium; FCS, foetal calf serum; GCA, giant cell arteritis;
NGF, nerve growth factor; PDGF, platelet-derived growth factor; TASMC,
temporal artery VSMC; VSMC, vascular smooth muscle cell.
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culture-supernatants from GCA patients
NGF sera concentrations were significantly higher in
GCA patients compared to controls (177 +/- 67.6 vs.145.5 +/- 66 pg/mL, P = 0.04) (Figure 5A) whereas no dif-
ference was found for BDNF (Figure 5A) or NT-3 (data
not shown). There was no correlation between NGF,
BDNF or NT-3 level and ischaemic events or inflamma-
tory syndrome. NGF and BDNF secretion was measured
in cell supernatants. NGF levels tended to be higher in
TASMCs from GCA patients (P = 0.06) (Figure 5B)
whereas no difference was detected for BDNF and NT-3
supernatants (data not shown).
Discussion
Despite substantial improvement in understanding the
pathophysiologic features of GCA, some mechanisms
still remain unclear, especially in relation to vascular re-
modelling. Herein, we report on the expression and
functions of NTs and their receptors, which are poten-
tially involved in vascular remodelling in GCA. It is
worth noting that NGF, BDNF and sortilin are signifi-
cantly overexpressed in different histological layers of
TAs in GCA patients compared to those of controls. In
addition, TrkB staining was significantly higher in the
TAs of GCA patients with a cranial ischaemic event.
TrkA and TrkC were not detected in patients or con-
trols, whereas NT-3 and p75NTR were enhanced only in
GCA patients. These data dealt with mRNA and protein
expression of NTs and NTRs in TASMCs from GCA pa-
tients and controls. Enhanced TrkB transcription was
observed in GCA cells whereas those of TrkA and TrkC
were feebly detected.
The expressions of NGF, BDNF and sortilin in the TAs
of GCA patients could be related to other inflammatory
disorders associated with localized expression of NTs.
Indeed, NGF is expressed in endothelial cells and kerati-
nocytes in patients with psoriasis [12], and NGF and
BDNF are present in the inflamed joints of patients with
rheumatoid arthritis [13,14]. Of note, constitutive NGF
expression and release in both human and mouse articu-
lar chondrocytes is enhanced by interleukin (IL)-1β [15].
Likewise, NTs are detected in other bronchial smooth
muscle cells during asthma [16] or sarcoidosis [17] and
their relationship with inflammatory cytokines, IL-1β
and interferon (IFN)-γ has been established by the in-
duction of NGF, and BDNF mRNA expression and se-
cretion in cell-culture supernatants [18,19]. Hence, the
overexpression of NTs and their receptors in TAs
from GCA patients could be, in part, related to the
presence of proinflammatory cytokines in all layers of
the inflamed arterial wall. Moreover, it has been dem-
onstrated that ischaemia contributes to the overex-
pression of some NTs and their related receptors, as
we have shown with the increased TrkB expression in
GCA patients with a cranial ischaemic event. Indeed,
in experimental arterial injury that leads to ischaemia,
enhanced expression of NGF, BDNF and their specific
Figure 5 Sera and supernatant concentrations of NGF and BDNF from GCA patients and controls. (A) NGF and BDNF sera concentrations
from patients with GCA (n = 30) compared to controls (n = 48) with a sera dilution of 1:100. (B) NGF TASMC-related supernatant concentration
from GCA patients (n = 8) compared to controls (n = 8). Supernatants were collected when VSMC reached 80% confluence, between passages 3
and 5. Experiments were performed in duplicate, with three independent ELISA assays and data are presented as pg/mL. BDNF, brain-derived
neurotrophic factor; ELISA, enzyme-linked immunosorbent assay; GCA, giant cell arteritis; NGF, nerve growth factor; TASMC, temporal artery VSMC;
VSMC, vascular smooth muscle cell.
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ine experimental model of atherosclerosis, the TrkB
receptor is overexpressed in neointimal VSMC cells
whereas decreased TrkB expression reduces atherosclerotic
lesions [20].Figure 6 Fine-tuning role of BDNF and TrkB in proliferation and migratio
receptor kinase B; TASMC, temporal artery vascular smooth muscle cell.Moreover, sortilin expression is enhanced in the ad-
ventitia and intima of TAs from GCA patients. This data
could be correlated with intimal TrkB overexpression, as
sortilin acts as an intracellular protein transporter for
immature NTs [21] and controls the regulation of BDNFn of TASMC. BDNF, brain-derived neurotrophic factor; TrkB, tropomyosin
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lated to BDNF and sortilin overexpression in TAs from
GCA patients. In addition, sortilin is also a co-receptor
for p75NTR, which was only observed in the TAs of GCA
patients. p75NTR is mostly absent in healthy controls
(HCs): its expression is enhanced by pathologic condi-
tions such as diabetes or atherosclerosis [3,5,23].
Serum NGF levels are significantly enhanced in GCA
patients, but not BDNF or NT-3. Such elevated NGF
levels have been previously reported in inflammatory
diseases such as Sjögren syndrome [24].
The proliferation effects of NTs are well described in
smooth muscle cells other than VSMCs, especially for
NGF and BDNF [25-28]. Given that isolation and expan-
sion in the culture of smooth muscle cells from tem-
poral arteries was previously reported [29], functional
studies of TASMCs isolated from GCA and controls
were performed in our study. Indeed, NGF promoted
proliferation in GCA-derived TASMCs similarly to
PDGF. Because TrkA was not detected in TASMCs, this
effect probably took place through p75NTR activation as
already described in brain tumor-initiating cells [30].
BDNF induced GCA-derived TASMCs proliferation de-
pending on TrkB as demonstrated by ANA-12, a specific
inhibitor of TrkB [10]. This effect, well reported in
smooth muscle cells in pulmonary hypertension [27] is
not significant probably because of our small number
samples. In GCA patients we have demonstrated that
BDNF promotes TASMCs migration rather than their
proliferation. Because both TrkB and BDNF were prom-
inently expressed in the same areas of GCA temporal ar-
teries, it is probable that BDNF activates TASMCs
migration from TAs of patients through its interaction
with TrkB. Our data are consistent with previous studies
on the effects of VSMCs on NTs [3,4,31]. Indeed, BDNF-
related migration was comparable to that observed with
PDGF, as described previously, [4] and was more consist-
ent than that observed with NGF.
Exploration of signalling pathways in our study showed
that PI3/Akt pathway seemed to be more activated than
ERK1/2 pathway in GCA patients compared to controls.
Though PI3/Akt signalling pathway can be activated by
TNF-α in human smooth muscle cells [32] or IL-1β in
rat brain astrocytes [33], our results are consistent with
BDNF-induced migration in human chondrosarcoma [34]
through a transducing signal involving TrkB.
Conclusions
Neurotrophins inducing proliferation and migration of
VSMC are potentially implicated in vascular remodelling
in GCA.
Taken together, our results provide new insights re-
garding the involvement of NTs and NTRs in the vascular
remodelling of GCA pathogenesis. Their overexpression inTAs from GCA patients could facilitate VSMC prolifera-
tion and migration from media to intima, thus contributing
to intimal hyperplasia. Particularly, a fine-tuning role of the
BDNF/TrkB axis is implicated in proliferation and migra-
tion of VSMC from GCA patients (and not from controls)
as demonstrated in vitro (Figure 6). However, further stud-
ies are needed to elucidate the signalling pathways that
allow VSMC migration in order to define new therapeutic
approaches for patients with GCA.
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